SCHEMBL3980405

SCHEMBL3980405

O=C1C=C(c2cnccn2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.38
NISCH Q9Y2I1 1/20 0.38
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA7 P36544 1/20 0.36
CHRNA4 P43681 1/20 0.36
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.33
RECQL P46063 1/20 0.33
PGR P06401 1/20 0.32
CYP1A2 P05177 1/20 0.32
KDM4E B2RXH2 1/20 0.31
NAPRT Q6XQN6 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31
CYP11B2 P19099 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HDAC4 P56524 1/20 0.31
ALOX5 P09917 1/20 0.31
ADORA3 P0DMS8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25224819 0.89 P2RX7 (0.36) P2RX7NISCHCHRNB2CHRNB4CHRNA3
SCHEMBL16679498 0.72 PIK3CA (0.34)
SCHEMBL27793790 0.71 NISCH (0.42) P2RX7NISCHCHRNB2CHRNB4CHRNA3
SCHEMBL29598957 0.68 NISCH (0.50) P2RX7NISCHALDH1A1HTTRECQL
SCHEMBL78566 0.68 NISCH (0.50) P2RX7NISCHALDH1A1HTTRECQL
SCHEMBL29454745 0.68 NISCH (0.50) P2RX7NISCHALDH1A1HTTRECQL
SCHEMBL3980920 0.68 P2RX7 (0.37) P2RX7NISCHCHRNB2CHRNB4CHRNA3
SCHEMBL19815621 0.68
SCHEMBL24924592 0.67 CYP11B1 (0.45) NISCHHTTCYP11B2HSP90AA1
SCHEMBL14053846 0.66 NISCH (0.48) P2RX7NISCHALDH1A1HTTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1874301-A4 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO INC (US) 2009-05-06 EP disclosed
US-20090054423-A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment MERCK SHARP & DOHME CORP. 2009-02-26 US disclosed
EP-1874301-A1 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT Merck & Co., Inc. (US) 2008-01-09 EP disclosed
WO-2006113150-A1 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054423-A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment FFAR1, HCAR1, GPR119 P2RX7 381/4885NISCH 87/4885CHRNB2 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.